33.53
Schlusskurs vom Vortag:
$34.02
Offen:
$34
24-Stunden-Volumen:
1.71M
Relative Volume:
1.08
Marktkapitalisierung:
$4.04B
Einnahmen:
$10.12M
Nettoeinkommen (Verlust:
$-280.49M
KGV:
-11.60
EPS:
-2.89
Netto-Cashflow:
$-188.51M
1W Leistung:
+5.77%
1M Leistung:
+14.40%
6M Leistung:
+11.47%
1J Leistung:
-27.58%
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RNA
Avidity Biosciences Inc
|
33.53 | 3.82B | 10.12M | -280.49M | -188.51M | -2.89 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-10 | Fortgesetzt | Goldman | Buy |
2025-06-24 | Eingeleitet | Bernstein | Outperform |
2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
2025-06-11 | Eingeleitet | Raymond James | Strong Buy |
2025-03-13 | Eingeleitet | Citigroup | Buy |
2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
2024-09-24 | Eingeleitet | Goldman | Buy |
2024-08-28 | Eingeleitet | Barclays | Overweight |
2024-05-03 | Eingeleitet | BofA Securities | Buy |
2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
2021-06-17 | Eingeleitet | Needham | Buy |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2020-07-07 | Eingeleitet | Cowen | Outperform |
2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com
What drives Avidity Biosciences Inc. stock priceRobust financial gains - Autocar Professional
Is Avidity Biosciences Inc. a good long term investmentTriple-digit returns - jammulinksnews.com
Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com
Why Avidity Biosciences Inc. stock attracts strong analyst attentionCapital Doubling Tips - beatles.ru
(RNA) On The My Stocks Page - news.stocktradersdaily.com
Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive (NASDAQ:RNA) - Seeking Alpha
RNA News Today | Why did Avidity Biosciences stock drop today? - MarketBeat
Goldman Sachs resumes coverage on Avidity Biosciences stock with Buy rating - Investing.com Canada
Avidity Biosciences, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Avidity Biosciences, Inc Rings the Opening Bell - Nasdaq
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces key milestones - Investing.com
Avidity Biosciences, Inc.(NasdaqGM: RNA) added to Russell 3000E Value Index - MarketScreener
(RNA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Avidity Biosciences’ Promising Phase 3 Study on FSHD Treatment: Market Implications - TipRanks
Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com
Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus
(RNA) Proactive Strategies - news.stocktradersdaily.com
Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus
The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com India
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Avidity Biosciences (RNA) Receives Strong Buy Rating from Raymond James | RNA Stock News - GuruFocus
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress – Company AnnouncementFT.com - Financial Times
Avidity's Muscular Dystrophy Drug Del-brax Gets FDA Accelerated Approval Path: Key Data Coming - Stock Titan
Avidity Biosciences holds annual stockholders meeting By Investing.com - Investing.com South Africa
Avidity Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
Avidity Biosciences holds annual stockholders meeting - Investing.com
Avidity Biosciences price target raised to $75 from $65 at Chardan - Yahoo Finance
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):